NK cells serve as a potential immunotherapeutic tool due to their innate ability to kill cancer cells. They play a crucial role in cancer prevention by providing immune surveillance, making them attractive candidates for immunotherapeutic tool. However, quite often NK cell can fail to recognize and eradicate residual cancer cells, resulting in cancer relapse and lower chance of survival. In this webinar, Prof. Mark Lowdell, Chief Scientific Officer of INmune Bio, Inc. discussed how primed NK cells become effective against resistant tumor cells, and how cell avidity measurements were used to depict a stronger binding of primed NK cells, resulting in improved tumor cell killing.
Key learning points:
- With cell avidity measurements, the team can rapidly distinguish NK sensitive- from NK-resistant tumor cells by quantifying amount of NK cells bound to cancer cells.
- In their research studies, the binding between resting NK cells and NK sensitive tumor cells depicted a higher avidity score, indicating the formation of a stronger immune synapse.
- Cell avidity measurements was used to depict stronger binding of INKmune-primed NK cells that eradicate residual disease.
